Human Genome Sciences reports results of mapatumumab Phase 2 trial for multiple myeloma

Download PDF Copy

Jun 9 2010

NewsGuard 100/100 Score

Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with bortezomib (Velcade) in patients with advanced multiple myeloma.

The results showed no difference in disease response or progression-free survival for the combination that included mapatumumab vs. the control group receiving bortezomib alone, and showed that mapatumumab was well tolerated in this study. HGS expects to present the results in full at an appropriate scientific meeting, hopefully later in 2010.

Source:

Human Genome Sciences

Posted in: Drug Trial News | Medical Condition News

Tags: Anthrax, Antibody, Apoptosis, Cancer, Cell, Genome, Hepatitis C, Lupus, Monoclonal Antibody, Multiple Myeloma, Myeloma, Nexavar, Oncology, Sorafenib

Comments (0)

Download PDF Copy

Suggested Reading

US study uncovers antiviral resistance in swine-origin influenza, urging enhanced pandemic surveillance

US study uncovers antiviral resistance in swine-origin influenza, urging enhanced pandemic surveillance

Genetic risk factors for long-COVID uncovered in a large multi-ethnic study

Genetic risk factors for long-COVID uncovered in a large multi-ethnic study

Genetic study uncovers key drivers of metabolic syndrome with brain tissue links

Genetic study uncovers key drivers of metabolic syndrome with brain tissue links

Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients

Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients

Adolescents' genetic risks tied to psychotic symptoms

Adolescents' genetic risks tied to psychotic symptoms

Genetic factors that make the bacteria behind cholera so dangerous uncovered

Genetic factors that make the bacteria behind cholera so dangerous uncovered

From crude lysate to purity with high-precision AAV capsid measurement with Bio-Rad's new ddPCR Kit

From crude lysate to purity with high-precision AAV capsid measurement with Bio-Rad's new ddPCR Kit

Study identifies six cancer susceptibility genes

Study identifies six cancer susceptibility genes

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Rare variant analysis reveals genetic spectrum of monogenic diabetes genes